Venous thrombosis and predictors of relapse ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Venous thrombosis and predictors of relapse in eosinophil-related diseases
Auteur(s) :
Reau, Valeriane [Auteur]
Centre d'Investigation Clinique Henri Mondor [CIC Henri Mondor]
Vallee, Alexandre [Auteur]
Hôpital Foch [Suresnes]
Terrier, Benjamin [Auteur]
Hôpital Cochin [AP-HP]
Plessier, Aurelie [Auteur]
Abisror, Noemie [Auteur]
Ackermann, Felix [Auteur]
Benainous, Ruben [Auteur]
Bohelay, Gerome [Auteur]
Chabi-Charvillat, Marie-Laure [Auteur]
Cornec, Divi [Auteur]
Desbois, Anne-Claire [Auteur]
Faguer, Stanislas [Auteur]
Freymond, Nathalie [Auteur]
Gaillet, Antoine [Auteur]
Hamidou, Mohamed [Auteur]
Killian, Martin [Auteur]
Le Jeune, Sylvain [Auteur]
Marchetti, Anne [Auteur]
Meyer, Guy [Auteur]
Osorio-Perez, Francisco [Auteur]
Panel, Kewin [Auteur]
Rautou, Pierre-Emmanuel [Auteur]
Rohmer, Julien [Auteur]
Simon, Nicolas [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Tcherakian, Colas [Auteur]
Vasse, Marc [Auteur]
Zuelgaray, Elina [Auteur]
Lefevre, Guillaume [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Kahn, Jean-Emmannuel [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Groh, Matthieu [Auteur]
Centre d'Investigation Clinique Henri Mondor [CIC Henri Mondor]
Vallee, Alexandre [Auteur]
Hôpital Foch [Suresnes]
Terrier, Benjamin [Auteur]
Hôpital Cochin [AP-HP]
Plessier, Aurelie [Auteur]
Abisror, Noemie [Auteur]
Ackermann, Felix [Auteur]
Benainous, Ruben [Auteur]
Bohelay, Gerome [Auteur]
Chabi-Charvillat, Marie-Laure [Auteur]
Cornec, Divi [Auteur]
Desbois, Anne-Claire [Auteur]
Faguer, Stanislas [Auteur]
Freymond, Nathalie [Auteur]
Gaillet, Antoine [Auteur]
Hamidou, Mohamed [Auteur]
Killian, Martin [Auteur]
Le Jeune, Sylvain [Auteur]
Marchetti, Anne [Auteur]
Meyer, Guy [Auteur]
Osorio-Perez, Francisco [Auteur]
Panel, Kewin [Auteur]
Rautou, Pierre-Emmanuel [Auteur]
Rohmer, Julien [Auteur]
Simon, Nicolas [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Tcherakian, Colas [Auteur]
Vasse, Marc [Auteur]
Zuelgaray, Elina [Auteur]
Lefevre, Guillaume [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Kahn, Jean-Emmannuel [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Groh, Matthieu [Auteur]
Titre de la revue :
Scientific Reports
Nom court de la revue :
Sci Rep
Numéro :
11
Pagination :
6388
Date de publication :
2021-03-18
ISSN :
2045-2322
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Eosinophils have widespread procoagulant effects. Eosinophilic cardiovascular toxicity mostly consists of endomyocardial damage or eosinophilic vasculitis, while reported cases of venous thrombosis (VT) are scarce. We aimed ...
Lire la suite >Eosinophils have widespread procoagulant effects. Eosinophilic cardiovascular toxicity mostly consists of endomyocardial damage or eosinophilic vasculitis, while reported cases of venous thrombosis (VT) are scarce. We aimed to report on the clinical features and treatment outcomes of patients with unexplained VT and eosinophilia, and to identify predictors of relapse. This retrospective, multicenter, observational study included patients aged over 15 years with VT, concomitant blood eosinophilia ≥ 1G/L and without any other moderate-to-strong contributing factors for VT. Fifty-four patients were included. VT was the initial manifestation of eosinophil-related disease in 29 (54%) patients and included pulmonary embolism (52%), deep venous thrombosis (37%), hepatic (11%) and portal vein (9%) thromboses. The median [IQR] absolute eosinophil count at VT onset was 3.3G/L [1.6-7.4]. Underlying eosinophil-related diseases included FIP1L1-PDGFRA-associated chronic myeloid neoplasm (n = 4), Eosinophilic Granulomatosis with Polyangiitis (n = 9), lymphocytic (n = 1) and idiopathic (n = 29) variants of hypereosinophilic syndrome. After a median [IQR] follow-up of 24 [10-62] months, 7 (13%) patients had a recurrence of VT. In multivariate analysis, persistent eosinophilia was the sole variable associated with a shorter time to VT relapse (HR 7.48; CI95% [1.94-29.47]; p = 0.015). Long-term normalization of eosinophil count could prevent the recurrence of VT in a subset of patients with unexplained VT and eosinophilia ≥ 1G/L.Lire moins >
Lire la suite >Eosinophils have widespread procoagulant effects. Eosinophilic cardiovascular toxicity mostly consists of endomyocardial damage or eosinophilic vasculitis, while reported cases of venous thrombosis (VT) are scarce. We aimed to report on the clinical features and treatment outcomes of patients with unexplained VT and eosinophilia, and to identify predictors of relapse. This retrospective, multicenter, observational study included patients aged over 15 years with VT, concomitant blood eosinophilia ≥ 1G/L and without any other moderate-to-strong contributing factors for VT. Fifty-four patients were included. VT was the initial manifestation of eosinophil-related disease in 29 (54%) patients and included pulmonary embolism (52%), deep venous thrombosis (37%), hepatic (11%) and portal vein (9%) thromboses. The median [IQR] absolute eosinophil count at VT onset was 3.3G/L [1.6-7.4]. Underlying eosinophil-related diseases included FIP1L1-PDGFRA-associated chronic myeloid neoplasm (n = 4), Eosinophilic Granulomatosis with Polyangiitis (n = 9), lymphocytic (n = 1) and idiopathic (n = 29) variants of hypereosinophilic syndrome. After a median [IQR] follow-up of 24 [10-62] months, 7 (13%) patients had a recurrence of VT. In multivariate analysis, persistent eosinophilia was the sole variable associated with a shorter time to VT relapse (HR 7.48; CI95% [1.94-29.47]; p = 0.015). Long-term normalization of eosinophil count could prevent the recurrence of VT in a subset of patients with unexplained VT and eosinophilia ≥ 1G/L.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Collections :
Date de dépôt :
2021-07-06T12:44:36Z
2022-01-19T10:25:02Z
2022-01-19T10:25:02Z